ENCell Co (XKRX:456070) Beginning Cash Position : ₩5,781 Mil (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is ENCell Co Beginning Cash Position?

ENCell Co's Beginning Cash Position for the quarter that ended in Dec. 2023 was ₩5,781 Mil.

ENCell Co's quarterly Beginning Cash Position declined from Dec. 2021 (₩7,201 Mil) to Dec. 2022 (₩5,899 Mil) and declined from Dec. 2022 (₩5,899 Mil) to Dec. 2023 (₩5,781 Mil).

ENCell Co's annual Beginning Cash Position declined from Dec. 2021 (₩7,201 Mil) to Dec. 2022 (₩5,899 Mil) and declined from Dec. 2022 (₩5,899 Mil) to Dec. 2023 (₩5,781 Mil).

ENCell Co Beginning Cash Position Historical Data

The historical data trend for ENCell Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENCell Co Beginning Cash Position Chart

ENCell Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

1,748.74

7,201.42

5,899.25

5,781.48

ENCell Co Quarterly Data
	Dec20	Dec21	Dec22	Dec23
Beginning Cash Position	1,748.74	7,201.42	5,899.25	5,781.48

ENCell Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

ENCell Co Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of ENCell Co's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

ENCell Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ENCell Co Ltd (XKRX:456070) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

701 Yeongdong-daero, 11th floor, Gangnam-gu, Seoul, KOR

Website

http://www.encellinc.com

ENCell Co Ltd is a biopharmaceutical company. The company is engaged in conducting biopharmaceutical contract development and manufacturing (CDMO) service business and cell, gene therapy new drug development business for rare/incurable muscle diseases such as Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, and sarcopenia.

ENCell Co Headlines

No Headlines